Reuters logo
Galapagos looking for acquisitions after drug deal
February 29, 2012 / 9:50 AM / 6 years ago

Galapagos looking for acquisitions after drug deal

AMSTERDAM (Reuters) - Galapagos is looking for acquisitions after it received $150 million euros in upfront payments from a deal with U.S. Abbott Laboratories (ABT.N) for its leading drug.

“It would have to fit into what we are already doing and make financial sense,” Chief Executive Onno van de Stolpe told a news conference on Wednesday.

Reporting by Anthony Deutsch, writing by Ben Deighton

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below